JBS (JBS) Q3 2025 Earnings Call Transcript

JBS reported record net sales of $22.6 billion and adjusted EBITDA of $1.8 billion (IFRS, 8.1% margin; U.S. GAAP comparable $1.6 billion, 7.2% margin) with net income of $581 million (EPS $0.52; adjusted $602 million, EPS $0.54). Free cash flow fell to $383 million, down $612 million YoY driven by a $319 million EBITDA decline, +$226 million CapEx and +$258 million working capital; leverage stood at 2.39x. Management completed a $600 million buyback program (repurchased $362 million this quarter), paid $1.2 billion in dividends, issued $570 million in agribusiness receivables (40-year tranche) lifting avg. debt maturity to 15.4 years at ~5.6% cost, and reiterated ~ $2.0 billion annual CapEx with working-capital needs of ~$1.3 billion (2025) and ~$700 million (2026). Key risks include U.S. beef supply tightness, hedging/derivative volatility, and avian flu impacts, while Seara export reopenings and planned U.S. pork capacity (ramps in 2027, targeting $500–$750 million revenue) underpin medium-term upside.

Analysis

JBS’s global footprint and recent capital moves create an asymmetric payoff: short-term earnings volatility from hedges and cyclical U.S. beef supply constraints is real, but balance-sheet restructuring (very long-dated local issuance) and aggressive buybacks shift the probability toward investor-friendly capital returns once Q4 hedging noise clears. The non-obvious offset is operational optionality — restored access to premium Seara markets will not just raise pack-level prices but reallocate previously-discounted volumes away from lower-margin destinations, decompressing unit economics across the Brazilian protein stack over 2-4 quarters.

Second-order supply effects matter: as Brazil/Australia reabsorb export demand that the U.S. cannot supply, Brazilian feed demand (corn/soy) will firm regionally, lifting local input costs and compressing margin tails for less-integrated domestic processors — a relative advantage for vertically integrated platforms like JBS. Meanwhile, the Iowa pork capacity builds are a latent multi-year optionality (material revenue + margin upside starting 2027) that is underpriced into near-term models because consensus treats 2026 as uniformly weak.

Risk vectors and timeframes are clear: expect Q4 mark-to-market and possible derivative cash-outs over weeks to months; herd rebuilding and cattle availability are 12–24 month stories; and 2027 is the inflection window for capitalized pork upside. The tactical implication: size exposure to the equity on pullbacks while hedging event gamma around the Q4 derivative unwind and funding-season liquidity points.

Key Decisions for Investors

• Long JBS (JBS) equity with a protective put: initiate on any >5% pullback from current levels, sizing to 2–4% of portfolio. Buy 9–12 month JBS puts to cap downside (~8–12% premium cost). Rationale: capital structure durability + premium-market access → 6–12 month upside (target +20–35%); hedge protects against Q4 hedging losses and commodity shocks.
• Directional trade on Pilgrim's Pride (PPC): buy a 4–7 month bull call spread ~20–25% OTM (or outright long if implied vol is low). Rationale: chicken/prepared foods momentum and limited capex lag → asymmetric near-term upside; risk limited to option premium, target 2.5–4x return if demand and mix sustain.
• Volatility calendar vs earnings/hedge unwind (JBS): sell near-term (30–60 day) implied volatility and buy 3–6 month volatility (calendar spread) ahead of Q4 reporting window. Rationale: management flagged a potential unwind of negative derivative cash flows — if realized, front-month vol should collapse; keep position size small and hard-stop if underlying moves >12% intraperiod.
• Event/timing pair for 2027 optionality: accumulate long exposure to JBS in tranches through 2026 (quarterly buys) to capture Iowa pork capacity ramp in 2027, funded by selling short-dated call overwrites in months without company events. Rationale: stages in exposure to avoid paying top price; expected IRR driven by 2027 margin expansion—risk is execution delays pushed beyond 2027.